Desmocollin-2 expression was significantly reduced in 91.7% of ACM patients, distinguishing ACM from controls and other cardiomyopathies with ROC AUC of 0.80 (P<0.0001).
Does desmocollin-2 (DSC2) expression level serve as a biomarker to discriminate arrhythmogenic cardiomyopathy from controls and other cardiomyopathies?
Reduced myocardial expression of desmocollin-2 (DSC2) serves as a robust diagnostic biomarker for arrhythmogenic cardiomyopathy, distinguishing it from other cardiomyopathies and controls.
Absolute Event Rate: 0% vs 0%
Aims: Arrhythmogenic cardiomyopathy (ACM) is a genetically-determined disease characterized by malignant arrhythmias and sudden cardiac death, particularly in young individuals. Mutations in desmosomal genes are a major cause of ACM, but the role of desmocollin-2 (DSC2) remains understudied. Methods and results: We conducted a multi-cohort study with 52 ACM patients, 29 with dilated cardiomyopathy (DCM), 17 with hypertrophic cardiomyopathy (HCM), and 45 controls. Immunofluorescence, immunohistochemical staining, and western blot were used to assess DSC2 expression. DSC2 expression was significantly reduced in ACM myocardium compared to controls and other cardiomyopathies (P < 0.0001), consistent across ACM subtypes and validated in an independent cohort. DSC2 down-regulation correlated with clinical characteristics such as age at onset of arrhythmia and heart transplantation. DSC2 reduction in the right ventricle effectively discriminated ACM patients from controls (ROC AUC = 0.8017, P < 0.0001) and distinguished ACM from other cardiac diseases. Immunohistochemical staining in the Swiss cohort confirmed that 11 out of 12 (91.7%) ACM cases exhibited significantly reduced DSC2 signal intensity compared to normal donors. RNA-Seq analysis revealed significant down-regulation of DSC2 genes in ACM tissues. Conclusion: DSC2 remodelling is a hallmark of ACM, harbouring significant diagnostic implications. DSC2 reduction is a robust biomarker for ACM, showing high sensitivity and specificity across different subtypes. Future research should elucidate the mechanisms underlying DSC2 down-regulation.
Ren et al. (Fri,) reported a other. Desmocollin-2 expression was significantly reduced in 91.7% of ACM patients, distinguishing ACM from controls and other cardiomyopathies with ROC AUC of 0.80 (P<0.0001).